Ken Griffin Sarepta Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 113,300 shares of SRPT stock, worth $2.18 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
113,300
Previous 127,800
11.35%
Holding current value
$2.18 Million
Previous $15.5 Million
53.47%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding SRPT
# of Institutions
507Shares Held
89MCall Options Held
1.39MPut Options Held
1.13M-
Black Rock Inc. New York, NY10.3MShares$199 Million0.04% of portfolio
-
Capital International Investors Los Angeles, CA9.06MShares$174 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.03MShares$174 Million0.01% of portfolio
-
State Street Corp Boston, MA4.07MShares$78.2 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X03.36MShares$64.7 Million0.12% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.68B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...